Theseus Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Theseus Pharmaceuticals, Inc. | THRX - NASDAQ |
$14.00-$16.00 | $16.00 | $20.80 | 10 million | 10/7/2021 |
| Jefferies, SVB Leerink, Cantor | ||||||
Co-Manager(s): Wedbush PacGrow
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-09-15 Terms Added 2021-09-30 | ||||||
Theseus Pharmaceuticals, Inc. Quote & Chart - Click for current quote - THRX
IPO Boutique aggregates information on public companies and private companies, such as "THRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Theseus Pharmaceuticals, Inc. (adapted from Theseus Pharmaceuticals, Inc. prospectus):
They are a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "THRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.